Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Company Deals Digital

SciClone Pharmaceuticals Partners with JD Healthcare to Pioneer Integrated Immune Health Management Model

Fineline Cube Apr 24, 2026
Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026
Company Deals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

Fineline Cube Apr 23, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC

Fineline Cube Apr 27, 2026
Company Drug

China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis

Fineline Cube Apr 24, 2026
Company Deals R&D

Siemens Healthineers AG and Shandong First Medical University’s College of Radiology Collaborate on Medical Imaging Metaverse

Fineline Cube Jan 31, 2024

Siemens Healthineers AG (ETR: SHL), a leading life sciences company based in Germany, has entered...

Company

Clinigen Expands Global Footprint with First Fully-Owned Subsidiary in Shanghai’s Free Trade Zone

Fineline Cube Jan 31, 2024

Clinigen, a UK-based medical and pharmaceutical services provider, has announced the establishment of its first...

Company Drug

European Commission Approves Takeda’s Hyqvia for Chronic Inflammatory Demyelinating Polyneuropathy

Fineline Cube Jan 31, 2024

The European Commission (EC) has granted regulatory approval to Takeda Pharmaceutical Company Limited (TYO: 4502)...

Company Deals

WuXi XDC Partners with Multitude Therapeutics and Signs MOU with Shanghai Huilian to Advance ADC Technologies

Fineline Cube Jan 31, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company

Shanghai Administration Imposes Hefty Fine on H&S Pharmaceutical for Substandard Drugs

Fineline Cube Jan 31, 2024

The Shanghai Municipal Medical Products Administration has disclosed that Hengshan (H&S) Pharmaceutical is under scrutiny...

Company

Shanghai Junshi Biosciences Forecasts 6.02% Revenue Growth in 2023 Driven by Commercialized Products

Fineline Cube Jan 31, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a biopharmaceutical company based in China,...

Company Deals

Regeneron Pharmaceuticals Acquires 2seventy Bio to Boost Cell Therapy Capabilities

Fineline Cube Jan 31, 2024

Regeneron Pharmaceuticals (NASDAQ: REGN) has announced the acquisition of U.S. biotechnology company 2seventy Bio Inc....

Policy / Regulatory

Hunan Province Hospitals Commit to Implementing Nationally Negotiated Drugs in Policy Seminar

Fineline Cube Jan 31, 2024

A policy seminar under the auspices of the Hunan Healthcare Security Administration bureau convened in...

Company

Pfizer Reports USD 58.5 Billion in Revenues Amid Post-Pandemic Sales Shifts and Oncology Pipeline Expansion

Fineline Cube Jan 31, 2024

Pfizer Inc. (NYSE: PFE) has reported a significant downturn in global revenues for the week,...

Company

Astellas Forges Partnership with Mass General Brigham to Boost Oncology and Rare Disease Research

Fineline Cube Jan 31, 2024

Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced a strategic partnership...

Company Deals

Shanghai CureGene Pharmaceutical Secures USD 14 Million in Series B Financing to Advance Cardiovascular Treatments

Fineline Cube Jan 31, 2024

Shanghai CureGene Pharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has announced the successful completion of...

Company Deals

Ping An Good Doctor Partners with Vcanbio to Pioneer Cell Health Management Services in China

Fineline Cube Jan 31, 2024

Ping An Healthcare and Technology Co., Ltd (HKG: 1833), commonly referred to as PingAn Good...

Company Deals Hospital

Mabwell Bioscience Extends Research Partnership with Fudan University Cancer Center

Fineline Cube Jan 31, 2024

Mabwell (Shanghai) Bioscience Co., Ltd., (SHA: 688062) has announced the renewal of its strategic research...

Company Drug

Hengrui Pharmaceuticals Scores First-Mover Status with FDA Approval for Generic Astagraf XL

Fineline Cube Jan 30, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Deals

Gilead Increases Stake in Arcus Biosciences and Invests in Anti-TIGIT Program

Fineline Cube Jan 30, 2024

Gilead (NASDAQ: GILD) has strengthened its 2020 collaboration agreement with US-based Arcus Biosciences (NYSE: RCUS)...

Company Drug

Takeda’s Gammagard Liquid Approved by FDA for Chronic Inflammatory Demyelinating Polyneuropathy

Fineline Cube Jan 30, 2024

The US Food and Drug Administration (FDA) has granted regulatory approval for Takeda’s (TYO: 4502)...

Company Hospital Policy / Regulatory

Shaanxi Province Unveils Ambitious Three-Year Plan to Boost Traditional Chinese Medicine Industry

Fineline Cube Jan 30, 2024

The provincial government of Shaanxi has unveiled the “Three Year Action Plan for Empowering Shaanxi...

Company Drug

AstraZeneca’s Enhertu Receives Priority Review for Expanded HER2-positive Solid Tumor Indication

Fineline Cube Jan 30, 2024

UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced that an indication extension filing for...

Company

MicroPort Scientific Corp. Forecasts 31%-34% Revenue Growth for Subsidiary MicroPort Endovascular in 2023

Fineline Cube Jan 30, 2024

Shanghai-based medical device conglomerate MicroPort Scientific Corp., (HKG: 0853) has issued a revenue and growth...

Company Deals

SANDT Secures Nearly RMB 200 Million to Boost X-ray System Development and Manufacturing

Fineline Cube Jan 30, 2024

SANDT, a Shanghai-based specialist in X-ray systems, has reportedly secured nearly RMB 200 million (USD...

Posts pagination

1 … 397 398 399 … 656

Recent updates

  • NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting
  • Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics
  • AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC
  • Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline
  • Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Others

Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics

Company Drug

AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC

Company R&D

Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.